STATUS: ACTIVE – Currently enrolling

“A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD”

Study Drug: Buntanetap

Phase 3

Eligibility: Age: 55-85 years, history of dementia

---

Apply for this research study